Liraglutide Gets Mixed Votes From Experts on Safety Issues

SILVER SPRING, MD. — The majority of a federal advisory panel has agreed that the available cardiovascular safety data on the antidiabetic drug liraglutide were adequate to rule out an unacceptable increase in cardiovascular risk when compared to other diabetes drugs.